---
title: "Yifang Biotech's Psoriasis Treatment Receives FDA Phase II Trial Approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279566692.md"
description: "Yifang Biotech has received FDA approval for a Phase II clinical trial of its psoriasis treatment, D-2570, as a monotherapy. The application reached the 30-day default period without objections, confirming the trial's approval under relevant regulations."
datetime: "2026-03-18T09:22:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279566692.md)
  - [en](https://longbridge.com/en/news/279566692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279566692.md)
---

# Yifang Biotech's Psoriasis Treatment Receives FDA Phase II Trial Approval

Yifang Biotech has announced that its application to the U.S. Food and Drug Administration (FDA) for a Phase II clinical trial of D-2570 as a monotherapy for psoriasis (PsO) has reached the 30-day default period without any objections from the FDA. According to Jin10, this means that the Phase II clinical trial for D-2570 as a monotherapy for PsO in the United States has officially been approved, in accordance with relevant regulations.

### Related Stocks

- [688382.CN](https://longbridge.com/en/quote/688382.CN.md)

## Related News & Research

- [TransThera reports promising tinengotinib results in advanced solid tumors](https://longbridge.com/en/news/286670762.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [10:47 ETFirst National Consortium Dedicated to Lobular Breast Cancer Research Launches in the United States](https://longbridge.com/en/news/286934052.md)